logo

Kala Pharmaceuticals, Inc. (KALA)



Trade KALA now with
  Date
  Headline
4/18/2018 8:38:28 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) 4Q18 Estimate To -0.56 From -0.61
4/18/2018 8:38:17 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) 3Q18 Estimate To -0.53 From -0.54
4/18/2018 8:37:59 AM Wedbush Is Lowering Kala Pharmaceuticals, Inc. (KALA) 2Q18 Estimate To -0.52 From -0.50
4/18/2018 8:37:49 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) 1Q18 Estimate To -0.49 From -0.45
4/9/2018 4:12:37 PM Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3/5/2018 8:05:50 AM Kala Pharmaceuticals Appoints Gregory Perry To Board
1/5/2018 7:06:01 AM Kala Reports Topline Results For Two Phase 3 Trials Of KPI-121 0.25% In Dry Eye Disease
1/5/2018 6:53:27 AM Kala Pharma Says FDA Accepts NDA For INVELTYS For Review
12/28/2017 4:26:12 AM Watch These 6 Biotech Stocks
12/22/2017 1:09:33 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target
12/5/2017 6:15:05 AM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target
11/30/2017 1:02:36 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target
11/13/2017 8:06:36 AM Kala Pharma Names Todd Bazemore COO